Verapamil in newly diagnosed children: Egyptian randomized trial
What this study tests
A newly registered phase 2/3 placebo-controlled trial testing whether oral verapamil preserves insulin secretion during the first six months after diagnosis. The registry reports recruitment in Egypt.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-09-04.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Children aged 10–18 within six weeks of starting insulin, with at least two positive islet autoantibodies. Important exclusions include cardiac conduction disease, low blood pressure and significant liver or kidney impairment. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted. The registry targets 70 participants and evaluates peak stimulated C-peptide at 24 weeks. These are planned measurements, not evidence of benefit in this cohort.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: Other regions. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Peak stimulated serum C-peptide concentration after mixed meal tolerance test — 24 weeks
The full picture
What the study asks
A newly registered phase 2/3 placebo-controlled trial testing whether oral verapamil preserves insulin secretion during the first six months after diagnosis. The registry reports recruitment in Egypt.
Who it involves
Children aged 10–18 within six weeks of starting insulin, with at least two positive islet autoantibodies. Important exclusions include cardiac conduction disease, low blood pressure and significant liver or kidney impairment. This is a summary; the full registry lists additional criteria.1
Design and timing
The registry lists 70 participants (estimated enrollment). Primary completion: 2027-02-20 (estimated). Study completion: 2027-03-20 (estimated). Estimated dates can change and do not mean results are available.1
Evidence and limits
No results posted. The registry targets 70 participants and evaluates peak stimulated C-peptide at 24 weeks. These are planned measurements, not evidence of benefit in this cohort.
Sources
- [1]Oral Verapamil Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes (NCT07804849) · Trial registry — Protocol and current registry status checked 16 September 2026.
ClinicalTrials.gov. NCT07804849. Record checked 16 September 2026; last update posted 2026-09-04.